Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer

Vanessa Di Lalla¹, Michael J Kucharczyk², Alexander W Wyatt³, Felix Y Feng⁴, Stephan Probst⁵, Gwenaelle Gravis⁶, Jonathan So⁷, Fred Saad⁸, Tamim Niazi⁹

Affiliations

¹ Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada.
² Department of Radiation Oncology, Nova Scotia Cancer Centre, Halifax, NS, Canada.
³ Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
⁴ Department of Radiation Oncology, University of California-San Francisco, San Francisco, CA, USA.
⁵ Department of Nuclear Medicine, Jewish General Hospital, Montreal, QC, Canada.
⁶ Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France.
⁷ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁸ Centre Hospitalier de l'Université de Montréal, Montreal Cancer Institute/CRCHUM, University of Montreal, Montreal, QC, Canada.
⁹ Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada. Electronic address: tniazi@jgh.mcgill.ca.

PMID: 35065838
DOI: 10.1016/j.eururo.2021.12.038

Editorial

Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer

Vanessa Di Lalla et al. Eur Urol. 2022 May.

. 2022 May;81(5):437-439.

doi: 10.1016/j.eururo.2021.12.038. Epub 2022 Jan 20.

Authors

Vanessa Di Lalla¹, Michael J Kucharczyk², Alexander W Wyatt³, Felix Y Feng⁴, Stephan Probst⁵, Gwenaelle Gravis⁶, Jonathan So⁷, Fred Saad⁸, Tamim Niazi⁹

Affiliations

¹ Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada.
² Department of Radiation Oncology, Nova Scotia Cancer Centre, Halifax, NS, Canada.
³ Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
⁴ Department of Radiation Oncology, University of California-San Francisco, San Francisco, CA, USA.
⁵ Department of Nuclear Medicine, Jewish General Hospital, Montreal, QC, Canada.
⁶ Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France.
⁷ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁸ Centre Hospitalier de l'Université de Montréal, Montreal Cancer Institute/CRCHUM, University of Montreal, Montreal, QC, Canada.
⁹ Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada. Electronic address: tniazi@jgh.mcgill.ca.

PMID: 35065838
DOI: 10.1016/j.eururo.2021.12.038

Abstract

Tumor biology may play an important role as an effective predictive biomarker that is complementary to functional imaging for metastatic hormone-sensitive prostate cancer.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer

Affiliations

Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical